论文部分内容阅读
To evaluate the efficacy of adjuvantchemotherapy after radical surgery for non-small-celllung cancer (NSCLC). Methods Seventy patients with NSCLC (stages Ⅰ -Ⅲ ) undergoing radical surgery were randomized intotwo groups. Group 1 (n = 35): combination group,which received adjuvant chemotherapy withcyclophosphamide 300 mg/m 2, vincristine 1. 4 mg/m 2,adriamycin 50 mg/m 2, and lomustine 50 mg/m 2 on day1, and cisplatin 20 mg/m 2 on days 1-5. Thetreatment was repeated every 4-6 weeks for 4 cycles,followed by oral administration of ftorafur (FT-207) 600-900 mg/d for 1 year. Group 2 (n = 35): surgerygroup, which received surgical treatment only. Results The overall 5-year survival rate was 48.6%in the combination group versus 31 .4% in the surgerygroup, and difference between the two groups was notStatistically significant (x 2 = 3.09, P > 0.05). The year survival rate for patients with stage Ⅲ diseasewas 44% and 20.8% in the combination and surgerygroups, respectively, showing a statistically significantdifference (x 2 = 5.28, P < 0.025). The 5-yearsurvival rates of patients in stages Ⅰ -Ⅱ in the twogroups were 60.0% and 54.5%, respectively, andwere not significantly different (x 2 = 0. 03, P > 0. 75). Conclusion Postoperative adjuvant chemotherapy provides statistically significant improvement in the 5 year survival rate only in patients with stage ⅢNSCLC.
To evaluate the efficacy of adjuvantchemotherapy after radical surgery for non-small-cell lung cancer (NSCLC). Methods Seventy patients with NSCLC (stages I-III) undergoing radical surgery were randomized intotwo groups. Group 1 (n = 35) which received adjuvant chemotherapy with cyclophosphamide 300 mg / m 2, vincristine 1. 4 mg / m 2, adriamycin 50 mg / m 2, and lomustine 50 mg / m 2 on day 1, and cisplatin 20 mg / m 2 on days 1-5. Group 2 (n = 35): surgerygroup, which received surgical treatment only. Results of this study were repeated every 4-6 weeks for 4 cycles, followed by oral administration of ftorafur (FT-207) 600-900 mg / d for 1 year. The overall 5-year survival rate was 48.6% in the combination group versus 31.4% in the surgery group, and difference between the two groups was not statistically significant (χ 2 = 3.09, P> 0.05) . The year survival rate for patients with stage Ⅲ diseasewas 44% and 20.8% in the combination and surgerygroups, respective The 5-yearurvival rates of patients in stages Ⅰ-Ⅱ in the twogroups were 60.0% and 54.5%, respectively, and were not significantly different (x ( × 2 = 5.28, P <0.025) 2 = 0.03, P> 0.75). Conclusion Postoperative adjuvant chemotherapy provides significant significant improvement in the 5-year survival rate only in patients with stage III NSCLC.